Sutro Biopharma Reports Exit Costs and Files Exhibits

TL;DR

Sutro Biopharma (STRO) filed an 8-K for exit costs and exhibits. Watch for updates.

AI Summary

On September 29, 2025, Sutro Biopharma, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing also included financial statements and exhibits. The company is located at 111 Oyster Point Blvd, South San Francisco, CA 94080.

Why It Matters

This filing indicates potential restructuring or divestiture activities within Sutro Biopharma, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Filings related to exit or disposal activities can signal significant business changes, potentially involving financial restructuring or operational shifts.

Key Players & Entities

• SUTRO BIOPHARMA, INC. (company) — Registrant
• September 29, 2025 (date) — Date of earliest event reported
• 111 Oyster Point Blvd, South San Francisco, California, 94080 (location) — Principal executive offices address
• 001-38662 (company_id) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value STRO The Nasdaq Global Ma
• $4.1million — force are estimated to be approximately $4.1million to $4.3 million, with a significant maj
• $4.3 m — ated to be approximately $4.1million to $4.3 million, with a significant majority of t

Filing Documents

• stro-20250929.htm (8-K) — 50KB
• stro-ex99_1.htm (EX-99.1) — 15KB
• 0001193125-25-223434.txt ( ) — 173KB
• stro-20250929.xsd (EX-101.SCH) — 26KB
• stro-20250929_htm.xml (XML) — 4KB

05 Costs Associated with Exit or Disposal Activities

Item 2.05 Costs Associated with Exit or Disposal Activities On September 29, 2025, Sutro Biopharma, Inc. (the "Company") announced further organizational restructuring to prioritize the advancement of its three preclinical ADC programs and its research and development collaborations. The restructuring is expected to extend the Company's runway into at least mid-2027 resulting from cost savings associated with the restructuring and certain expected near-term milestone payments. Following further prioritization of the ADC programs, the Company expects initial clinical data to be available from STRO-004, its next-generation Tissue Factor-targeting exatecan ADC, in 2026. As part of the corporate restructuring, the Company plans to reduce its workforce by approximately one-third. The total cash payments and costs related to the further prioritization of the ADC programs and reducing the workforce are estimated to be approximately $4.1million to $4.3 million, with a significant majority of these amounts expected to be paid in the fourth quarter of 2025. These estimates are subject to a number of assumptions and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the corporate restructuring. A copy of the press release announcing the corporate restructuring is attached as Exhibit 99.1 to this Current Report on Form 8-K.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Sutro Biopharma, Inc. announcing operational restructuring intended to extend cash runway through key milestones. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding anticipated preclinical and clinical development activities; timing of announcements of IND submissions, clinical results, trial initiation, and other regulatory filings; outcome of discussions with regulatory authorities; potential benefits of the Company's product candidates and platform; potential business development and partnering transactions; potential market opportunities for the Company's product candidates; the timing and receipt of anticipated future milestone payments; the Company's expected cash runway; and the expected costs and cost reductions associated with the restructuring, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in the Company's filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 13, 2025. Any of these risks and uncertainties could materially and adversely affect the Company's results of operations, which would, in turn, have a significant and adverse impact on the Company's stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events. SIGNATURE Pursuant to the requirements of the Securities Ex

View Full Filing

View this 8-K filing on SEC EDGAR